Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SNY crawled date : 2022 - 09 - 05 save search
Global Treatment Resistant Depression Market to Surpass US$ 1,545.6 Million by 2030 - Coherent Market Insights
Published: 2022-09-05 (Crawled : 19:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: -4.59%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.93%
H: 10.14%
C: 3.79%
ATAI | $1.85 -3.14% -3.24% 940K
|
Manufacturing
|
| O: 1.61%
H: 0.45%
C: -4.97%
VTRS | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: -0.84%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.63%
H: 0.35%
C: -0.57%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.54%
H: 3.26%
C: 1.28%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 0.47%
H: 1.39%
C: 0.15%
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.75%
H: 1.49%
C: 0.21%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.35%
H: 0.0%
C: 0.0%
treatment global depression market
Global Osteoarthritis Drugs Market to surpass US$ 16,184.9 million by 2030 - Coherent Market Insights
Published: 2022-09-05 (Crawled : 18:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
RDUS | $18.41 -0.61% -0.61% 220K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
AVNS | $18.71 0.05% 0.0% 180K
|
Health Technology
| Email alert
Add to watchlist
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
osteoarthritis global market
Vitiligo Treatment Market Size Worth US$ 2.42 Billion With CAGR of 6.14% from 2022 to 2030 | Exclusive Report by Growth Plus Reports
Published: 2022-09-05 (Crawled : 14:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
ALPMF | $9.17 43.47% 16K
|
Health Technology
| Email alert
Add to watchlist
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
| Email alert
Add to watchlist
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
treatment report plus growth market
Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Published: 2022-09-05 (Crawled : 12:00) - prnewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
dupixent children
Outlook on the Hereditary Angioedema Global Market to 2030 - Size, Share, Outlook, and Opportunity Analysis
Published: 2022-09-05 (Crawled : 11:00) - prnewswire.com
CNTG | $0.463 0.43% 0.43% 79K
|
Commercial Services
| Email alert
Add to watchlist
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
| Email alert
Add to watchlist
BCRX | $4.44 -1.33% -1.35% 4.7M
|
Health Technology
| Email alert
Add to watchlist
ARWR | $22.33 -1.24% -1.25% 960K
|
Health Technology
| Email alert
Add to watchlist
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
| Email alert
Add to watchlist
global market hereditary angioedema
Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022
Published: 2022-09-05 (Crawled : 08:00) - biospace.com/
IPHA | $2.48 5.53% 5.24% 9.4K
|
Health Technology
| Email alert
Add to watchlist
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
IPHYF | $2.65 104.6% 300
|
Health Technology
| Email alert
Add to watchlist
pharma platform phase 2b
Press Release: Evolution of the Board of Directors
Published: 2022-09-05 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
Published: 2022-09-05 (Crawled : 06:00) - globenewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
dupixent children
FDA Review: Immusoft, BioCryst, Intellia and More
Published: 2022-09-05 (Crawled : 05:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
fda
Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity
Published: 2022-09-05 (Crawled : 01:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
obesity chinese trial phase 2
ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers
Published: 2022-09-04 (Crawled : 00:00) - prnewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
libtayo potential
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.